Works Cited

Babson, K.A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: A review of the literature. Current Psychiatry Reports, 19(23).

Bergamaschi, M.M., Queiroz, R.H.C., Zuardi, A.W., Crippa, J.A.S. (2011). “Safety and Side Effects of Cannabidiol, a Cannabis Sativa Constituent.” Current Drug Safety. 6(4). 

Breus, M.J. (2019). How CBD can improve your sleep, mood, and health. Psychology Today.

Centers for Disease Control and Prevention. (2016). “1 in 3 adults don’t get enough sleep: A good night’s sleep is critical for good health.”

Clarke, R., & Merlin, M. (2016). Cannabis domestication, breeding history, present-day genetic diversity, and future prospects.Critical Reviews in Plant Sciences, 35(5-6). 293-327.

DEA Administrative Law Hearing, DEA. (August 22, 2005). 

De Petrocellis, L., Cascio, M.G., & Di Marzo, V. (2004). The endocannabinoid system: A general view and latest additions. British Journal of Pharmacology. 141(5), 765-774.

Di Marzo, V., Bifulco, M., & De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nature Reviews, 3, 771-784. 

Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1999). Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neurosciences, 21, 521–528. 

Fasinu, P.S., et al. (2016). “Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.” Pharmacotherapy. P.781-796. 

FDA (2018).” Facts about the Current Good Manufacturing Practices (CGMPs)”. U.S. Food & Drug Administration

Fine, M.D., P., & Rosenfield, M. (2013). “The Endocannabinoid System, Cannabinoids, and Pain.” Rambam Maimonides Medical Journal. 4(4); e0022

Flaccus, G. (2019). “Growers hope standards bring order to hemp industry ‘mess’”. AP News, June 15, 2019.

Gallily, R., Yekhtin, Z., & Hanuš, L. (2015). Overcoming the bell-shaped dose: Response of cannabidiol by using cannabis extract enriched in cannabidiol. Pharmacology & Pharmacy, 6, 75-85.

Grof, C. (2018). Cannabis, from plant to pill. British Journal of Clinical Pharmacology84(11), 2463–2467.

Harvard Medical School. (2017). Learn the risk of sleep aids. Harvard Health Letter.

Izzo, A., Borrelli, F., Capasso, R., Di Marzo, V., & Mechoulam, R. (2009). “Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb.” Trends in Pharmacological Sciences.  

Jung, Y. & St. Louis, E.K. (2016).  “Treatment of REM Sleep Behavior Disorder.” Current Treatment Options Neurology. 18(50). DOI 10.1007/s11940-016-0433-2

Kumar Chattu, V., et. al. (2018). “Insufficient sleep syndrome: Is it time to classify it as a major noncommunicable disease?” Sleep Science, 11, pp 56-64.

Levine, J. (1997, May). “Controlled trials of inositol in psychiatry.” Journal of the European College of Neuropsychopharmacology.  7(2):pp. 147-155.

Ligresti, A., Petrosino, S., & Di Marzo, V. (2009). From endocannabinoid profiling to ‘endocannabinoid therapeutics.’ Current Opinion in Chemical Biology, 13, 321-331.

Maroon, J., & Bost, J. (2018). Review of the neurological benefits of phytocannabinoids.Surgical Neurology International9, 91.

Martin-Santos, R., et al., (2012). “Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.” Current Pharmaceutical Design. 18(32). P.4966-4979.

McAllister S., Soroceanu, L., & Desprez, P. (2015). The antitumor activity of plant-derived non-psychoactive cannabinoids. Journal of Neuroimmune Pharmacology, 10(2): 255-267.

Meixner, M. (2018 August 15). “Inositol: Benefits, Side Effects and Dosage.” Healthline. 

Mohan, C.P. (June 14, 2017). “Melatonin: What Is It and Can It Help You Sleep?” WebMD

Moskowitz, M. (2017). Medical cannabis: A guide for patients, practitioners, and caregivers. Virginia Beach: Köehler Books.

Mudge, E., Murch, S., & Brown, P.  (2018). Chemometric analysis of cannabinoids: Chemotaxonomy and domestication syndrome. Scientific Reports, 8,

Nagarkatti, P., Pandey. R, Rieder, S., Hegde, V., & Nagarkatti, M. (2009).
Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry,
1(7), 1333-1349.

Pacher, P., Bátkai, S. & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462.

Peri, C. (February 13, 2014). “10 Things to Hate About Sleep Loss.” WebMD. 

Pertwee, R. (2006). Cannabinoid pharmacology: The first 66 years. British Journal of Pharmacology, 147, S163-S171.

Piccirillo, J.F. (2007). Melatonin. Progress in Brain Research. 166. pp 331-333.

Reggio, P. (2010). Endocannabinoid binding to the cannabinoid receptors: What is known and what remains unknown. Current Medicinal Chemistry17(14):

Rupp, T. L., Acebo, C., & Carskadon, M.A. (2007). “Evening Alcohol Suppresses Salivary Melatonin in Young Adults.” Chronobiology International. 24(3). pp 463-470. DOI: 10.1080/07420520701420675

Russo, E. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163, 1344-1364.

Sawler, J., Stout, J., Gardner, K., Hudson, D., Vidmar, J., Butler, L.,Page, J., & Myles, S. (2015). The genetic structure of marijuana and hemp. PloS One10(8).

Shannon M.D., S., Lewis N.D, N., Lee PA-C, H., & Hughes PhD., S. (2019). “Cannabidiol in Anxiety and Sleep: A Large Case Series.” The Permanente Journal. (23) pp 18-41. 

Todd, S., & Arnold, J. (2015). Neural correlates of interactions between cannabidiol and delta-9-tetrahydrocannabinol in mice: Implications for medical cannabis.British Journal of Pharmacology, 173:53-65.